Santen Pharmaceutical Co., Ltd.

SNPHY · OTC
Analyze with AI
3/31/2025
3/31/2024
3/31/2023
3/31/2022
Operating Activities
Net Income$36$27-$15$27
Dep. & Amort.$18$18$17$17
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$0$0$0
Change in WC$10$14-$5$5
Other Non-Cash-$3$14$40-$3
Operating Cash Flow$61$73$37$46
Investing Activities
PP&E Inv.-$7-$9-$25-$36
Net Acquisitions$0-$0-$3-$3
Inv. Purchases$0-$0-$1-$1
Inv. Sales/Matur.$0$4$2$4
Other Inv. Act.-$2-$0-$0$1
Investing Cash Flow-$8-$6-$27-$35
Financing Activities
Debt Repay.-$3-$2$4$20
Stock Issued$0$0$0$0
Stock Repurch.-$38-$17-$26-$0
Dividends Paid-$12-$12-$13-$12
Other Fin. Act.$0-$3-$3-$3
Financing Cash Flow-$53-$34-$37$6
Forex Effect-$1$4$2$4
Net Chg. in Cash$93$37-$25$20
Supplemental Information
Beg. Cash$95$58$83$63
End Cash$93$95$58$83
Free Cash Flow$54$62$13$10
Santen Pharmaceutical Co., Ltd. (SNPHY) Financial Statements & Key Stats | AlphaPilot